Two-year mortality in survivors of acute exacerbations of chronic obstructive pulmonary disease: A North Indian study

Parvaiz A Koul, Hilal A Dar, Rafi A Jan, Sanaullah Shah, Umar Hafiz Khan
Department of Internal and Pulmonary Medicine, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

ABSTRACT

Objectives: Data about long-term mortality of Indian patients following acute exacerbation of chronic obstructive pulmonary disease (AECOPD) are scant. We set out to study the 2-year mortality in north Indian patients following discharge after AECOPD.

Materials and Methods: One hundred and fifty-one (96 male) patients admitted for AECOPD and discharged were followed for 2 years at 3, 6, 12, 18, and 24 months for mortality. Statistical analysis was performed to identify risk factors associated with mortality.

Results: Sixty (39.7%) of the 151 recruited died during the 24 months of follow-up, 30 (19.8%) at 3-month, 43 (28.5%) at 6-month, 49 (32.4%) at 1-year, 55 (36.4%) at 18-month, and 60 (39.7%) at 2 years. There was no mortality in Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage I (0 of 6 cases), whereas it was 12.3% (n = 8 of 65 patients) in GOLD Stage II, 41.7% (n = 15 of 36 cases), in GOLD Stage III, and 84.1% (n = 37 of 4 cases), of patients with GOLD Stage IV. Mortality was associated with 6-min walk distance, oxygen saturation, low body mass index, history of congestive heart failure, and St. George Respiratory Questionnaire score.

Conclusion: Indian patients discharged after AECOPD have a high 2-year mortality. Measures to reduce the frequency of exacerbations need to be routinely adopted in patients with COPD.

KEY WORDS: Acute exacerbation, chronic obstructive pulmonary disease, GOLD, mortality

INTRODUCTION

An acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is an acute worsening of dyspnea, cough, and/or sputum production/change in the quality that is beyond normal day-to-day variation and sufficient to warrant a change of medications.[1] Although adequate drugs and therapeutic interventions are available to control the clinical symptoms of chronic obstructive pulmonary disease (COPD) and reduce airway inflammation, exacerbations in COPD lead to an accelerated decline in lung functions[2,3] reduced health status and quality of life,[4] and increased risk of death. Apart from in-hospital mortality during an acute exacerbation, studies on long-term mortality after hospitalization have shown a 1-year mortality from 22%[5] to 43%[6] and a 2-year mortality of 36%[7] to 49%,[8] thus being one of the worst clinical outcomes in a chronic disorder regardless of the organ involvement.

COPD is a frequently encountered clinical problem in India with AECOPD as a common cause for hospitalization. Recently, a high prevalence was reported in Northern India by the Burden of Lung Disease investigators,[8,9] and thus it is expected that there is a high frequency of
hospitalizations as a result of AECOPD with considerable morbidity and mortality. A recent study from South India recorded an in-hospital mortality of 12% in AECOPD.\(^\text{[10]}\) While long-term mortality following exacerbations has been well described in the developed countries, there is a paucity of literature from the developing countries and no data are available from India. The present study was designed against this backdrop to prospectively examine the postdischarge mortality of patients surviving an AECOPD and analyze the factors associated with increased mortality.

**MATERIALS AND METHODS**

A prospective observational study was conducted at Sher-I-Kashmir Institute of Medical Sciences, Srinagar, 750-bedded tertiary care hospital. One hundred and fifty-one patients of AECOPD (COPD defined as postbronchodilator forced expiratory volume 1 s (FEV\(_1\))/forced vital capacity) ratio of <0.7) who were discharged after a hospital stay of at least 24 h were recruited for the study.

Demographic data, clinical history, and clinical examination were recorded in all patients on a predefined proforma. The patients were investigated as per the protocol that included routine blood chemistry, hemogram, blood gas analysis, radiograph of the chest, echocardiography, sputum and blood cultures, etc. Computed tomography scan of the chest was performed when indicated. Patients were managed with bronchodilators, steroids, oxygen (delivered through nasal prongs, nasal or venturi masks as necessitated), antibiotics and noninvasive or invasive ventilation. Information regarding a number of prior hospital admissions if any, history of smoking was collected. At discharge, arterial blood gas determinations were repeated and a spirometry performed. All comorbidities were recorded and a 6-min walk test performed for walking distance. St. George’s Respiratory Questionnaire (SGRQ) was administered after standardization and validation in a locally understandable vernacular for the three components scores: symptoms, activities, and impact. A total score was calculated from all three components, with zero indicating no health impairment and 100 representing maximum impairment. A 6-min walk test was done at discharge to determine the 6-min walking distance (6MWD).

All the patients were followed after discharge for 2 years with a follow up every 2 months and a telephonic enquiry in the case of a missed follow-up. The primary study end points was death.

Patients were excluded from the study if death occurred during the hospital stay, or there was pulmonary edema at hospital admission or the patients hospitalized for a cause other than the acute exacerbation of COPD.

Analysis of the data was performed using Stata 8.0 (Stata Corporation, College Station, Texas, USA). Chi-square test and the unpaired t-test as appropriate were used when comparing patients who died during the study. The relationship between survival time and patients’ characteristics was determined using Kaplan–Meier survival analysis and Cox regression. Multivariate analysis was also performed with the Cox model after adjustment for global initiative for chronic obstructive lung disease (GOLD) stages. The analyzed independent variables were chosen based on statistical significance in the bivariate analysis and on clinical relevance. Health status, 6MWD, \(\text{SaO}_2\) at discharge, and age were entered as continuous variables, whereas gender, co-morbidities, and treatment were entered as categorical variables. The proportional hazard assumption was tested for all the independent variables in the models, and no violation was detected \((P > 0.1)\). The study protocol was reviewed and approved by the hospital research and ethics committee. Values have been expressed as mean ± standard deviation (SD) and a value of \(P < 0.05\) was considered statistically significant.

**RESULTS**

The 151 patients comprised 96 males and 55 females with median age of 65 years (mean + SD = 65.4 ± 9.0 years). One hundred and four patients were tobacco smokers, with hookah smoking being the most common form of smoking \((n = 55)\), whereas 43 smoked only cigarettes. The distribution of cases as per GOLD stages included Stage I \((n = 6)\), Stage II \((n = 65)\), Stage III \((n = 36)\), and Stage IV \((n = 44)\). The patients presented with various symptoms that included symptoms included breathlessness (88.1%), cough (69.5%), altered sugar levels (60%), ischemic heart disease \((n = 25)\), and muscle wasting (body mass index [BMI] <18 kg/m\(^2\)) \((n = 19)\). Electrocardiographic evidence of right ventricular dominance was seen in 91 patients. Frequent exacerbations (defined as two or more exacerbation per year) occurred in 31.8% of COPD patients. During the course of the study, about 40.6% of males and 40% of female patients were readmitted again. Frequent exacerbations were related to the severity of COPD according to GOLD stage \((P = 0.005)\).

The at-discharge 6MWD ranged from 82 to 498 meters \((\text{mean ± SD 241.2 ± 97.1 m})\), being 245.2 ± 97.7 \((82, 496)\) in male patients and 234.2 ± 96.6 \((98, 498)\) in females \((P = 0.505)\). Oxygen saturation ranged from 78 to 96.5% \((\text{mean ± SD 90.2 ± 3.6%})\).

Sixty (39.7%) of the 151 recruited died during 24 months of follow-up. The number of patients who died at various periods of follow-up was 30 (19.8%) at 3-month, 43 (28.5%) at 6-month, 49 (32.4%) at 1-year, 55 (36.4%) at 18-month, and 60 (39.7%) at 2 years of follow-up. There was no mortality in GOLD Stage I \((0\) of 6 cases) while it was 12.3% \((n = 8\) of 64 cases) in GOLD Stage II \((0\) of 6 cases) while it was 12.3% \((n = 8\) of 64 cases) in GOLD Stage III \((0\) of 6 cases) while it was 12.3% \((n = 8\) of 64 cases) in GOLD Stage IV \((0\) of 6 cases) while it was 12.3% \((n = 8\) of 64 cases).
of 65 patients) in GOLD Stage II \( (n = 15 \text{ of 36 cases}) \) and 41.7% \( (n = 37 \text{ of 44 cases}) \) in GOLD Stage III [Figure 1]. About 84.1% of patients in GOLD Stage IV died during the 2-year of follow-up. Patients with a total SGRQ score of >60 had a much higher mortality (82.5%) compared to those with a SGRQ score of <60 (9.1%) [Figure 2]. Patients with frequent exacerbation (32% of the patients) had increased mortality with respect to those who had <2 exacerbations per year.

On multilogistic regression, factors associated with increased mortality included lower health status as assessed using SGRQ [Figure 2], a lower \( \text{SaO}_2 \) at discharge \( (>90\%) \) [Figure 3] and a lower 6MWD [Figure 4]; mortality being high when 6MWD was between 150–250 M. In addition, a lower arterial \( pH <7.35 \) and a higher \( \text{pCO}_2 >45 \text{ mmHg} \) at presentation were associated with increased 2-year mortality. Higher mortality also occurred in patients with history of heart failure \( (P = 0.000) \), those with a body mass index <18 Kg/m\(^2\) \( (P = 0.000) \) and [Figure 5]. The use of long-acting \( \beta_2 \) agonists alone or in combination with inhaled corticosteroids was associated with decreased mortality when compared to those patients who received neither of these medications \( (P = 0.000) \).

**DISCUSSION**

Our study demonstrates that mortality rates after an exacerbation are high in North-Indian patients with COPD, the 2-year mortality rates being 39.7% while that at 1-year of discharge being 32.4%. The study, to the best of our knowledge, is the only study performed in India even as other researchers from elsewhere have reported mortality rates in this subset of patients to vary between 23% and 49% [Table 1].

The mortality in our patients was directly proportional to the stage of the COPD among the patients with a demonstrable increase in mortality in direct relation to the higher stages of COPD, ranging from 12.3% in stage 2 to 84% in GOLD Stage IV. Mortality rates in COPD have been found to correlate with the reducing lung function,\(^{[19-21]} \) with a step-wise increase and a pronounced increase in risk at a level of FEV1 below 50% predicted, suggesting a threshold effect in mortality risk at this level. Reduced baseline lung function has been reported to be a predictor of mortality by other investigators as well [Table 1]. Thus the data suggest that exacerbation is an added insult to the inexorable increase in morbidity and
Table 1: Comparison of the mortality rates following exacerbations of chronic obstructive pulmonary disease and identified risk factors

| Authors (year)     | Patients                          | 1-year mortality | 2-year mortality | Risk factors                                                                 |
|--------------------|-----------------------------------|------------------|------------------|-------------------------------------------------------------------------------|
| Connors et al.[9]  | 1016 patients with severe exacerbation | 43%              | 49%              | FEV<sub>1</sub>, BMI, age, PaO<sub>2</sub>                                      |
| Almagro et al.[10] | 135 patients after severe exacerbation | 22%              | 35.6%            | Age, women, SGRQ, previous severe exacerbations, PaCO<sub>2</sub>             |
| Groenewegen et al.[11] | 171 patients with severe exacerbation | 23%              | 23%              | PaCO<sub>2</sub>, age                                                        |
| Kim et al.[12]    | 482 patients after ED visit        | 23%              | -                | Age, comorbidities, previous severe exacerbations                             |
| Gudmundsson et al.[13] | 416 patients                      | -                | 29.3%            | Age, SGRQ score, lower pulmonary function, diabetes                          |
| Coleta et al.[14] | 78 patients using LTOT            | 15.4%            | -                | BDI, PaO<sub>2</sub>, PaCO<sub>2</sub>, SGRQ                               |
| Fan et al.[15]    | 603 patients                      | 7.5%             | -                | -                                                                             |
| Gershon et al.[16] | >30,000 patients from Canadian registry | 4.3%–5.7%       | -                | -                                                                             |
| Piquet et al.[17] | 1824 patients with severe exacerbation | 16.8%           | -                | Age, lower BMI, lung cancer, cardiovascular comorbidity, previous severe exacerbations, LTOT |
| Ho et al.[18]     | 4029 patients with severe exacerbations | 22%              | -                | Age, comorbidity                                                             |
| Müllerova et al.[19] | 2138 patients                    | 5.1%             | -                | Severe exacerbations, longer hospital stay                                     |
| Mekov et al.[20]  | 152 patients                      | 7.2%             | -                | Age, FEV, value, severe exacerbation in previous year and reduced quality of life, GOLD stage, heart failure, health status, 6MWD, BMI, hypoxia |
| Present study (Koul et al.) | 151 patients                 | 32.4%            | 39.7%            | -                                                                             |

ED: Emergency department, LTOT: Long-term oxygen therapy, BMI: Body mass index, FEV<sub>1</sub>: Forced expiratory volume 1 s, SGRQ: St. George’s Respiratory Questionnaire, BDI: Beck depression inventory, 6MWD: 6-min walking distance, GOLD: Global initiative for chronic obstructive lung disease

Figure 5: Kaplan–Meier survival curves in relation to the body mass index

mortality of Indian patients with COPD with advancing stage of COPD, defined on the basis of previous GOLD guidelines.

The patients with heart failure had a higher mortality (P < 0.001) than those without heart failure. Congestive heart failure and cor pulmonale have been reported to shorten survival time,[9] whereas Gudmundsson et al.[11] reported that cardiovascular co-morbidity was a risk factor for increased mortality only in those patients with a lower health status. Coexistent cardiac disease has been shown to be a risk factor for mortality in patients with COPD exacerbation.[22] Furthermore, ischemic heart disease and/or congestive heart failure were reported to increase the rate of treatment failure, thus contributing to the worsening of the patients’ condition. Our study also demonstrated that concomitant heart disease had a negative effect on survival and that cardiac co-morbidity is a risk factor of poor outcome, particularly in moderate–severe COPD patients (P < 0.001). Contrary to our results, no association between cardiac co-morbidity and the outcome was demonstrated previously in very severe COPD patients (FEV<sub>1</sub> <35% predictor and use of supplemental oxygen therapy).[23] The reason for this differing result may be the fact that when lung disease is severe, impairment in pulmonary function prevails over cardiac disease.

Health status (as assessed by SGRQ) had a direct relationship with the mortality in patients of COPD, with patients having SGRQ >60 having a higher mortality than those with SGRQ scores of ≤60 (P < 0.001). In the study by Gudmundsson et al.,[11] lower health status was related to higher mortality. This was true both for the total score on SGRQ as well as for the three subscales of activity, impact, and symptoms. Domingo-Salvany et al., in a study on male outpatients, reported that SGRQ and SF-36 total scores were independently associated with total mortality and respiratory mortality.[24]
We found that the patients of COPD with BMI of <18 kg/m² had higher mortality (P < 0.001). Two of our two patients of COPD had BMI >30 kg/m² and both of them died during the study. However, due to a small sample size of COPD patients with BMI >30 kg/m², we cannot draw an inference regarding the relationship of a high BMI with mortality. The “Obesity paradox” described in heart failure[21] has been proposed to be operative in patients with COPD too, with overweight and obese having a decreased risk of death compared with those with normal weight (hazard ratio 0.9, 95% confidence interval 0.7–1.0).[21] However, caution has to be observed in this oversimplification because increased BMI has not been found to be protective against fat-free mass depletion in COPD which is a feature of the preferential loss of muscle tissue in this disorder.[26] In addition, COPD is now a recognized risk factor for cardiovascular disease[23] and thus, further studies are needed to address this confounding factor in the mortality of patients with COPD.

Patients with increased effort tolerance in the current study as evidenced by 6MWD had a direct correlation with 2-year mortality, with a 97% mortality in patients with a 6MWD of <150 meters (P < 0.001), 53% mortality in patients with a 6MWD of 151–250 M and no mortality in patients with 6MWD of >350 m. Other studies carried out previously also have demonstrated that decreased distance walked during 6MWD is associated with increased mortality, being an independent predictor of mortality.[27] Since this is a simple measure to perform, we believe that 6MWD is an excellent prognostic marker for patients who survive a COPD exacerbation.[25]

Patients with hypoxia (PaO₂ <90%) at discharge had an increased mortality (P < 0.001) and mortality was higher among in those with a PaCO₂ >45. Costello et al. revealed in their study that PCO₂ at discharge was a better predictor of survival than PCO₂ on hospital admission in patients with respiratory failure and that reversible hypercapnia was associated with better prognosis. There was a lack of significance of low PO₂ at discharge which was explained by the use of long-term oxygen therapy (LTOT) at home after discharge in hypoxic patients.[28] When followed for prolonged periods the prognosis of hypoxic patients tends to improve and nearly becomes equal to nonhypoxic patients.[29] However, in the present study most of the patients with SaO₂ <90% at discharge were not using home oxygen therapy on a regular basis on recommended lines and those patients who were having the facility of home oxygen used it inadequately. This might explain the role of persistent hypoxia as a predictor of mortality in our patients as against earlier studies. Oxygen therapy in our patient population poses difficulties on account of financial reasons. An oxygen concentrator is ill afforded by a significant group of the population, and they resort to using refill cylinders and in an attempt to let the cylinder last for a greater period, they end up using oxygen for short intervals of time and with low flows so that in effect a significant percentage of patients receive inadequate LTOT. Additionally those with oxygen concentrators often face power shutdowns resulting in concentrators not working and the patients either resort to no oxygen or a low flow through a spare cylinder, if at all at hand.

While we did not demonstrate any correlation between the age and mortality in our patients, other investigators have reported higher mortality in patients with higher age.[30] The highest rate of mortality was seen in the 85-year-old and older age group 365 days after discharge while the lowest rate was the 30-day mortality of those aged 65–74 years.[30] Only 8.6% our of COPD patients were ≥80 years of age while the majority of the patients of COPD were ≥69 years of age. Hence, a significant impact of age as a co-variable was not manifest. Our study is limited by the fact that autopsies for causes of death were not available even as limited verbal autopsies attributed the mortality to progressive lung disease in majority of the participants.

**CONCLUSION**

We conclude that long term mortality in survivors of hospitalized AECOPD patients is high, being 32.4% at one year and 39.7% at 2 years was 32.4% after 1-year and 39.7% after 2-year of follow-up. The various factors associated with increased mortality (P < 0.001) were heart failure, lower health status (SGRQ total score >60), worse lung function (GOLD stage) 6MWD <150m and frequent exacerbations. Appropriate strategies aimed at reducing frequency and severity of exacerbations in COPD are warranted.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117 5 Suppl 2:398S-401S.
2. Donaldson GC, Seemungal TA, Bowmhik A, Wiedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
3. Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: Results from the lung health study. Am J Respir Crit Care Med 2001;164:358-64.
4. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698-702.
5. Almagro P, Calbo E, Ochoa de Echaguén A, Barreiro B, Quintana S, Heredia JL, et al. Mortality after hospitalization for COPD. Chest 2002;121:1441-8.
6. Connors AF Jr., Dawson NV, Thomas C, Harrell FE Jr., Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Am J Respir Crit Care Med 1996;154(4 Pt 1):959-67.
7. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest
Koul, et al.: 2-year mortality in AECOPD

8. Burney P, Jithoo A, Kato B, Janson C, Mannino D, Nizankowska-Mogilnicka E, et al. Chronic obstructive pulmonary disease mortality and prevalence: The associations with smoking and poverty – A BOLD analysis. Thorax 2014;69:465-73.

9. Koul PA, Hakim NA, Malik SA, Khan UH, Patel J, Gnatiuc L, et al. Prevalence of chronic airflow limitation in Kashmir, North India: Results from the BOLD study. Int J Tuberc Lung Dis 2016;20:1399-404.

10. Kim S, Clark S, Camargo CA Jr. Mortality after an emergency department visit for exacerbation of chronic obstructive pulmonary disease. COPD 2006;3:75-81.

11. Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik C, Brøndum E, et al. Mortality in COPD patients discharged from hospital: The role of treatment and co-morbidity. Respir Res 2006;7:109.

12. Cola KD, Silveira LV, Lima DF, Rampinelli EA, Godoy I, Godoy I. Predictors of first-year survival in patients with advanced COPD treated using long-term oxygen therapy. Respir Med 2008;102:512-8.

13. Fan VS, Ramsey SD, Giardino ND, Make BJ, Emery CF, Diaz PT, et al. Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med 2007;167:2345-53.

14. Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: A population-based study. Arch Intern Med 2010;170:560-5.

15. Piquet J, Chavaillon JM, David P, Martin F, Blanchon F, Roche N; French College of General Hospital Respiratory Physicians (CPHG). High-risk patients following hospitalisation for an acute exacerbation of COPD. Eur Respir J 2013;42:946-55.

16. Ho TW, Tsai YJ, Ruan SY, Huang CT, Lai F, Yu CJ; HINT Study Group. In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: A nationwide population-based study. PLoS One 2014;9:e114866.

17. Müllerova H, Maselli DJ, Locantore N, Vestbo J, Hurst JR, Wedzicha JA, et al. Hospitalized exacerbations of COPD: Risk factors and outcomes in the ECLIPSE cohort. Chest 2015;147:999-1007.

18. Mekov E, Slavova Y, Tsakova A, Genova MP, Kostadinov DT, Minchew D, et al. One-year mortality after severe COPD exacerbation in Bulgaria. PeerJ 2016;4:e2788.

19. Peto R, Speizer FE, Cochrane AL, Moore F, Fletcher CM, Tinker CM, et al. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease.

Results from 20 years of prospective observation. Am Rev Respir Dis 1983;128:491-500.

20. Ekberg-Aronsson M, Peahson K, Nilsson JA, Nilsson PM, Löfdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005;6:98.

21. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: Data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003;58:388-93.

22. Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, et al. Acute exacerbation of COPD: Factors associated with poor treatment outcome. Chest 2000;117:662-71.

23. Antonelli Incalzi R, Fusco L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:12794-800.

24. Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Félez M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:680-5.

25. Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: Findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006;173:79-83.

26. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993;147:1151-6.

27. Gerard DA, Lovett L, Benoit-Connors ML, Reardon JZ, ZuWallack RL. Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 1996;9:431-5.

28. Costello R, Deegan P, Fitzpatrick M, McNicholas WT. Reversible hypercapnia in chronic obstructive pulmonary disease: A distinct pattern of respiratory failure with a favorable prognosis. Am J Med 1997;102:239-44.

29. Cooper CB, Waterhouse J, Howard P. Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy. Thorax 1987;42:105-10.

30. Nie JX, Wang L, Uppshur RF. Mortality of elderly patients in Ontario after hospital admission for chronic obstructive pulmonary disease. Can Respir J 2007;14:485-9.